This phase III study assessed the efficacy and safety of sacubitril/valsartan compared with
those of olmesartan in Japanese patients with essential hypertension. Patients (n= 1161 …

This study assessed the efficacy and safety of angiotensin receptor neprilysin inhibitor
sacubitril/valsartan vs olmesartan in Asian patients with mild‐to‐moderate hypertension …

A majority of patients with hypertension fail to achieve blood pressure (BP) control despite
treatment with commonly prescribed drugs. This randomized, double‐blind phase III trial …

Abstract Sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor-neprilysin
inhibitor, demonstrated significant reductions in office and 24 h ambulatory blood pressure …

Background: Sacubitril/valsartan (LCZ696) has progressed to be one of the most promising
medication since its approval for chronic heart failure with reduced ejection fraction. Recent …

OBJECTIVE Systolic hypertension is common in elderly patients and remains a challenge to
treat effectively. The efficacy and safety of sacubitril/valsartan (LCZ696), a first-in-class …

A multicenter, randomized, placebo-controlled, double-masked, parallel-group study was
performed to compare the efficacy and safety of valsartan 20, 80, 160, and 320 mg with …

We compared the systolic blood pressure (SBP)-lowering efficacy and safety of crystalline
valsartan/sacubitril (LCZ696, an angiotensin receptor blocker–neprilysin inhibitor) 400 mg …

The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new
angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary …

Background: Losartan, the first of the angiotensin II receptor blockers (ARBs) to be
introduced, has been studied extensively in comparison with other classes of …